Tyrosine kinase inhibitors in cancer therapy

Clinical Biochemistry

Volumn 37, Issue 7, 2004, Pages 618-635

  Madhusudan, Srinivasan ^a   Ganesan, Trivadi S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer; Clinical trials; Tyrosine kinase inhibitors

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADAPHOSTIN; AG 13925; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBF 1000; CANERTINIB; CEP 2583; CEP 701; CETUXIMAB; CGP 59326 A; CGP 76030; CGP 77675; CP 654577; DAB 389 EGF; DT 385; EMD 82633; ERLOTINIB; GE 572016; GEFITINIB; GFB 116; GTP 14564; GW 2286; IMATINIB; IMC 1 C 11; LAPATINIB; MATUZUMAB; MDX 447; MIDOSTAURIN; MV 833; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PD 0713074; PD 116285; PD 1173952; PELITINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINOXALINE DERIVATIVE; SEMAXANIB; SU 4984; SU 5406; SUNITINIB; TAK 165; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VGA 1102;

ACNE; ANOREXIA; BONE MARROW SUPPRESSION; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRY SKIN; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LIVER TOXICITY; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; PRURITUS; RASH; REVIEW; SKIN TOXICITY; STOMATITIS; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VOMITING;

CLINICAL TRIALS; FORECASTING; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MODELS, BIOLOGICAL; NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 3042634240     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.05.006     Document Type: Review

References (177)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934
2. Krupa A., Srinivasan N. The repertoire of protein kinases encoded in the draft version of the human genome: atypical variations and uncommon domain combinations. Genome Biol. 3:2002;. [RESEARCH0066.1-.0066.14]
3. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene. 19:2000;5548-5557
4. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225
5. Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos. Trans. R. Soc. Lond., B Biol. Sci. 353:1998;583-605
6. Weiner H.L., Zagzag D. Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer. Cancer Invest. 18:2000;544-554
7. Ben-Bassat H. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr. Opin. Invest. Drugs. 2:2001;1539-1545
8. Lee D.C., Chan K.W., Chan S.Y. RET receptor tyrosine kinase isoforms in kidney function and disease. Oncogene. 21:2002;5582-5592
9. Indo Y. Genetics of congenital insensitivity to pain with anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV. Clinical, biological and molecular aspects of mutations in TRKA(NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Clinic. Auton. Res. 12(Suppl. 1):2002;I20-I32
10. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365
11. Grandis J.R., Chakraborty A., Zeng Q., Melhem M.F., Tweardy D.J. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J. Cell. Biochem. 69:1998;55-62
12. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 37(Suppl. 4):2001;S9-S15
13. Tandon A.K., Clark G.M., Chamness G.C., Ullrich A., McGuire W.L. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol. 7:1989;1120-1128
14. Meden H., Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur. J. Obstet. Gynecol. Reprod. Biol. 71:1997;173-179
15. Sadasivan R., Morgan R., Jennings S., Austenfeld M., Van Veldhuizen P., Stephens R., et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol. 150:1993;126-131
16. Selvaggi G., Scagliotti G.V., Torri V., Novello S., Leonardo E., Cappia S., et al. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer. 94:2002;2669-2674
17. Zhou H., Randall R.L., Brothman A.R., Maxwell T., Coffin C.M., Goldsby R.E. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J. Pediatr. Hematol. Oncol. 25:2003;27-32
18. Taniguchi M., Nishida T., Hirota S., Isozaki K., Ito T., Nomura T., et al. Effect of c-KIT mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 59:1999;4297-4300
19. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br. J. Haematol. 121:2003;775-777
20. Naeem M., Dahiya M., Clark J.I., Creech S.D., Alkan S. Analysis of c-KIT protein expression in small-cell lung carcinoma and its implication for prognosis. Hum. Pathol. 33:2002;1182-1187
21. Peters G., Gongoll S., Langner C., Mengel M., Piso P., Klempnauer J., et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003
22. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 100:2002;59-66
23. Fox S.B., Gasparini G., Harris A.L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2:2001;278-289
24. Arinaga M., Noguchi T., Takeno S., Chujo M., Miura T., Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 97:2003;457-464
25. Parr C., Jiang W.G. Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int. J. Oncol. 23:2003;533-539
26. Eggert A., Ikegaki N., Liu X.G., Brodeur G.M. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin. Padiatr. 212:2000;200-205
27. Baykal C., Ayhan A., Al A., Yuce K. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol. Oncol. 88:2003;123-129
28. Oda Y., Sakamoto A., Saito T., Kinukawa N., Iwamoto Y., Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-Met correlates with poor prognosis in synovial sarcoma. Hum. Pathol. 31:2000;185-192
29. Ueki T., Fujimoto J., Suzuki T., Yamamoto H., Okamoto E. Expression of hepatocyte growth factor and its receptor c-Met proto-oncogene in hepatocellular carcinoma. Hepatology. 25:1997;862-866
30. Rochlitz C., Lohri A., Bacchi M., Schmidt M., Nagel S., Fopp M., et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia. 13:1999;1352-1358
31. Lin W.C., Li A.F., Chi C.W., Chung W.W., Huang C.L., Lui W.Y., et al. Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin. Cancer Res. 5:1999;1745-1751
32. Verstovsek S., Kantarjian H., Manshouri T., O'Brien S., Faderl S., Talpaz M., et al. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer. 94:2002;1517-1521
33. Homer J.J., Greenman J., Drevs J., Marme D., Stafford N.D. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma. Head Neck. 24:2002;773-778
34. Gascoyne R.D., Aoun P., Wu D., Chhanabhai M., Skinnider B.F., Greiner T.C., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 93:1999;3913-3921
35. Aligayer H., Boyd D.D., Heiss M.M., Abdalla E.K., Curley S.A., Gallick G.E. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 94:2002;344-351
36. Olavarria E., Kanfer E., Szydlo R., Kaeda J., Rezvani K., Cwynarski K., et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 97:2001;1560-1565
37. O'Dwyer M. Multifaceted approach to the treatment of BCR-ABL-positive leukemias. Oncologist. 7(Suppl. 1):2002;30-38
38. Gleissner B., Gokbuget N., Bartram C.R., Janssen B., Rieder H., Janssen J.W., et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 99:2002;1536-1543
39. Miyazaki T., Kato H., Nakajima M., Sohda M., Fukai Y., Masuda N., et al. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer. 89:2003;140-145
40. Toyama T., Iwase H., Yamashita H., Hara Y., Omoto Y., Sugiura H., et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 189:2003;97-102
41. Al-Obeidi F.A., Lam K.S. Development of inhibitors for protein tyrosine kinases. Oncogene. 19:2000;5690-5701
42. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93:2002;79-98
43. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer. 38(Suppl. 5):2002;S11-S18
44. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:2002;46265-46272
45. Laird A.D., Cherrington J.M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Invest. Drugs. 12:2003;51-64
46. Fry D.W. Mechanism of action of erbB tyrosine kinase inhibitors. Exp. Cell Res. 284:2003;131-139
47. Denny W.A. Irreversible inhibitors of the erbB family of protein tyrosine kinases. Pharmacol. Ther. 93:2002;253-261
48. Mellinghoff I.K., Tran C., Sawyers C.L. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 62:2002;5254-5259
49. Slichenmyer W.J., Elliott W.L., Fry D.W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol. 28:2001;80-85
50. Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J. 7(Suppl. 3):2001;S134-S138
51. Buchdunger E., O'Reilly T., Wood J. Pharmacology of imatinib (STI571). Eur. J. Cancer. 38(Suppl. 5):2002;S28-S36
52. Nishimura N., Furukawa Y., Sutheesophon K., Nakamura M., Kishi K., Okuda K., et al. Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. Oncogene. 22:2003;4074-4082
53. Glossmann H., Presek P., Eigenbrodt E. Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent, transforming protein kinase, pp60src. Naunyn-Schmiedeberg's Arch. Pharmacol. 317:1981;100-102
54. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262:1987;5592-5595
55. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20:2002;1S-13S
56. Farah R.A., Clinchy B., Herrera L., Vitetta E.S. The development of monoclonal antibodies for the therapy of cancer. Crit. Rev. Eukaryotic Gene Expression. 8:1998;321-356
57. Hudson P.J. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11:1999;548-557
58. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:1999;5209-5218
59. Posey J.A., Ng T.C., Yang B., Khazaeli M.B., Carpenter M.D., Fox F., et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. 9:2003;1323-1332
60. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 8:2002;17-23
61. Madhusudan S., Harris A.L. Drug inhibition of angiogenesis. Curr. Opin. Pharmacol. 2:2002;403-414
62. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22:2001;201-207
63. Blaskovich M.A., Lin Q., Delarue F.L., Sun J., Park H.S., Coppola D., et al. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat. Biotechnol. 18:2000;1065-1070
64. Chen C.L., Levine A., Rao A., O'Neill K., Messinger Y., Myers D.E., et al. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies. J. Clin. Pharmacol. 39:1999;1248-1255
65. Murphy J.R., vanderSpek J.C. Targeting diphtheria toxin to growth factor receptors. Semin. Cancer Biol. 6:1995;259-267
66. Wild R., Dhanabal M., Olson T.A., Ramakrishnan S. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. Br. J. Cancer. 83:2000;1077-1083
67. Disis M.L., Knutson K.L., McNeel D.G., Davis D., Schiffman K. Clinical translation of peptide-based vaccine trials: the HER-2/neu model. Crit. Rev. Immunol. 21:2001;263-273
68. Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5:1999;1289-1297
69. Disis M.L., Rinn K., Knutson K.L., Davis D., Caron D., dela Rosa C., et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 99:2002;2845-2850
70. Zeng Q., Kanter P.M., Dhir R., Gooding W.E., Huang L., Grandis J.R. Lack of toxicity of EGFR antisense gene therapy. J. Exp. Ther. Oncol. 2:2002;174-186
71. Andrews D.W., Resnicoff M., Flanders A.E., Kenyon L., Curtis M., Merli G., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol. 19:2001;2189-2200
72. Endo S., Zeng Q., Burke N.A., He Y., Melhem M.F., Watkins S.F., et al. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther. 7:2000;1906-1914
73. Hasan J., Jayson G.C. VEGF antagonists. Expert Opin. Biol. Ther. 1:2001;703-718
74. Mousses S. Harnessing the power of RNA interference to advance anticancer drug development. Mol. Cancer Ther. 2:2003;217-218
75. Zhang L., Yang N., Mohamed-Hadley A., Rubin S.C., Coukos G. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303:2003;1169-1178
76. Dancey J., Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev., Drug Discov. 2:2003;296-313
77. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2:1996;561-566
78. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104
79. Manley P.W., Cowan-Jacob S.W., Buchdunger E., Fabbro D., Fendrich G., Furet P., et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer. 38(Suppl. 5):2002;S19-S27
80. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340:1999;1330-1340
81. Deininger M.W., Goldman J.M., Lydon N., Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 90:1997;3691-3698
82. Kasper B., Fruehauf S., Schiedlmeier B., Buchdunger E., Ho A.D., Zeller W.J. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother. Pharmacol. 44:1999;433-438
83. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91:1999;163-168
84. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037
85. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042
86. Druker B.J. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur. J. Cancer. 38(Suppl. 5):2002;S70-S76
87. Johnson J.R., Bross P., Cohen M., Rothmann M., Chen G., Zajicek A., et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin. Cancer Res. 9:2003;1972-1979
88. Wisniewski D., Lambek C.L., Liu C., Strife A., Veach D.R., Nagar B., et al. Characterization of potent inhibitors of the BCR-ABL and the c-KIT receptor tyrosine kinases. Cancer Res. 62:2002;4244-4255
89. Demetri G.D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur. J. Cancer. 38(Suppl. 5):2002;S52-S59
90. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121
91. Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S., Fletcher C.D., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 20:2001;5054-5058
92. Dagher R., Cohen M., Williams G., Rothmann M., Gobburu J., Robbie G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8:2002;3034-3038
93. van Oosterom A.T., Judson I.R., Verweij J., Stroobants S., Dumez H., Donato di Paola E., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 38(Suppl. 5):2002;S83-S87
94. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6:2000;3319-3326
95. Soria J.C., Johnson B.E., Chevalier T.L. Imatinib in small cell lung cancer. Lung Cancer. 41(Suppl. 1):2003;S49-S53
96. Gunby R.H., Cazzaniga G., Tassi E., Le Coutre P., Pogliani E., Specchia G., et al. Sensitivity to imatinib but low frequency of the TEL/PDGFRb fusion protein in chronic myelomonocytic leukemia. Haematologica. 88:2003;408-415
97. Cortes J., Giles F., O'Brien S., Thomas D., Albitar M., Rios M.B., et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 97:2003;2760-2766
98. Sawyers C.L. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J. Clin. Oncol. 20:2002;3568-3569
99. Kilic T., Alberta J.A., Zdunek P.R., Acar M., Iannarelli P., O'Reilly T., et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60:2000;5143-5150
100. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R.K., Heldin C.H., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61:2001;2929-2934
101. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 359:2002;1577-1578
102. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:2003;1201-1214
103. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 102:2003;3093-3096
104. Grunwald V., Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. 95:2003;851-867
105. Sirotnak F.M. Studies with ZD1839 in preclinical models. Semin. Oncol. 30:2003;12-20
106. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62:2002;2554-2560
107. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063
108. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv. Cancer Res. 78:2000;31-101
109. Anderson N.G., Ahmad T., Chan K.C., et al. Effects of ZD1839 (Iressa), a novel EGF receptor tyrosine kinase inhibitor on breast cancer cell proliferation and invasiveness. Breast Cancer Res. Treat. 2000;64. [abstract]
110. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892
111. Houghton P.J., Cheshire P.J., Harwood F.C. Evaluation of ZD1839 (Iressa) alone or in combination with Irinotecan (CPT-11) against pediatric solid tumour xenografts. Clin. Cancer Res. 6(Suppl.):2000;4542s. [abstract]
112. Ranson M., Hammond L.A., Ferry D., Kris M., Tullo A., Murray P.I., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:2002;2240-2250
113. Negoro S., Nakagawa K., Fukuoka M., Kudoh S., Tamura T., Yoshimura N., et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours [abstract no. 1292]. Proc. ASCO. 20:2001
114. Baselga J., Herbst R., LoRusso P., Rischin D., Ranson M., Plummer M., et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability [abstract no. 686]. Proc. ASCO. 19:2000
115. Goss G.D., Hirte H., Lorimer I., Miller W., Stewart D.J., Batish G., et al. Final results of the dose escalation phase of a phase I pharmacokinetic (PK), pharmacodynamic (PD) and biological activity study of ZD1839: NCIC CTG Ind.122 [abstract no. 335]. Proc. ASCO. 20:2001
116. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20:2002;110-124
117. Fukuoka M., Yano S., Giaccone G., Tanura T., Nakagawa K., Douillard J., et al. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1) [abstract no. 1188]. Proc. ASCO. 21:2002
118. Kris M.G., Natale R.B., Herbst R., Lynch T.J., Prager D., Belani C.P., et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract no. 1166]. Proc. ASCO. 21:2002
119. Ronald N.B. Geftinib (Iressa): the first effective EGFR-targeted agent in non-small cell lung cancer. 2nd international symposium on signal transduction modulators in cancer therapy:2003;Amsterdam, The Netherlands. Vol.; abstract no. O.21
120. Ranson M., Herbst R., Fukuoka M., Lynch T. Skin toxicity is not a clinically meaningful prognostic marker for tumor response to geftinib ('Iressa', ZD1839) in pre-treated patients with advanced non-small-cell lung cancer. 2nd international symposium on signal transduction modulators in cancer therapy. 2003;Amsterdam, The Netherlands. Vol.; abstract no. C.02
121. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann. Oncol. 13:2002;2. [abstract 4]
122. Johnson D.H., Herbst R., Giaccone G., et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann. Oncol. 13:2002;127. [abstract 468]
123. Sridhar S.S., Seymour L., Shepherd F.A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4:2003;397-406
124. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:1997;4838-4848
125. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291:1999;739-748
126. Akita R.W., Sliwkowski M.X. Preclinical studies with erlotinib (Tarceva). Semin. Oncol. 30:2003;15-24
127. Ng S.S., Tsao M.S., Nicklee T., Hedley D.W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol. Cancer Ther. 1:2002;777-783
128. Herbst R.S. Erlotinib (Tarceva): an update on the clinical trial program. Semin. Oncol. 30:2003;34-46
129. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19:2001;3267-3279
130. Grunwald V., Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. 30:2003;23-31
131. Allen L.F., Lenehan P.F., Eiseman I.A., Elliott W.L., Fry D.W. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol. 29:2002;11-21
132. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 95:1998;12022-12027
133. Gieseg M.A., de Bock C., Ferguson L.R., Denny W.A. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs. 12:2001;683-690
134. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1:2001;85-94
135. Bruns C.J., Solorzano C.C., Harbison M.T., Ozawa S., Tsan R., Fan D., et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60:2000;2926-2935
136. Barbacci E.G., Pustilnik L.R., Rossi A.M., Emerson E., Miller P.E., Boscoe B.P., et al. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res. 63:2003;4450-4459
137. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106
138. Zhu Z., Bohlen P., Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets. 2:2002;135-156
139. Smolich B.D., Yuen H.A., West K.A., Giles F.J., Albitar M., Cherrington J.M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-KIT) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 97:2001;1413-1421
140. Kuenen B.C., Tabernero J., Baselga J., Cavalli F., Pfanner E., Conte P.F., et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9:2003;1648-1655
141. Kuenen B.C., Rosen L., Smit E.F., Parson M.R., Levi M., Ruijter R., et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20:2002;1657-1667
142. Laird A.D., Vajkoczy P., Shawver L.K., Thurnher A., Liang C., Mohammadi M., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60:2000;4152-4160
143. Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 61:2001;1464-1468
144. Fabbro D., Manley P.W. Su-6668. SUGEN. Curr. Opin. Invest. Drugs. 2:2001;1142-1148
145. Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Muller M., et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60:2000;4819-4824
146. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2000;2178-2189
147. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62:2002;4645-4655
148. Miknyoczki S.J., Chang H., Klein-Szanto A., Dionne C.A., Ruggeri B.A. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin. Cancer Res. 5:1999;2205-2212
149. George D.J., Dionne C.A., Jani J., Angeles T., Murakata C., Lamb J., et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 59:1999;2395-2401
150. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62:2002;7284-7290
151. Kelly L.M., Yu J.C., Boulton C.L., Apatira M., Li J., Sullivan C.M., et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:2002;421-432
152. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101:2003;3597-3605
153. Spiekermann K., Dirschinger R.J., Schwab R., Bagrintseva K., Faber F., Buske C., et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and
154. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443
155. Levis M., Allebach J., Tse K.F., Zheng R., Baldwin B.R., Smith B.D., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99:2002;3885-3891
156. Susva M., Missbach M., Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol. Sci. 21:2000;489-495
157. Sawyer T.K., Shakespeare W., Wang Y., Metcalf R., Sundaramoorthi T., Keenen R. A new class of small-molecule therapeutics for osteolytic bone metastasis: discovery of novel bone-targeted src tyrosine kinase inhibitors having potent in vitro and in vivo activities [abstract no. 977]. Proc. ASCO. 22:2003
158. Sattler M., Pride B.Y., Gramlich J.L., Chu S.C., Quinnan L.A., Ma P., et al. The novel small molecule drug SU-MI-2 induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase [abstract no. 1005]. Proc. AACR. 44:2003
159. Saijo N., Nishio K.N. Mechanisms of ZD1839 resistance and ZD1839 induced pulmonary fibrosis. 2nd international symposium on signal transduction modulators in cancer therapy. 2003;Amsterdam, The Netherlands. Vol.; abstract no. O.20
160. Paterson S.C., Smith K.D., Holyoake T.L., Jorgensen H.G. Is there a cloud in the silver lining for imatinib? Br. J. Cancer. 88:2003;983-987
161. Koizumi F., Taguchi F., Shimoyama T., Saijo N., Nishio K. Mechanism of resistance to epidermal growth factor receptor inhibitor ZD1839: a role for inhibiting phosphorylation of EGFR at Tyr 1068 [abstract no. 1001]. Proc. AACR. 44:2003
162. Jones H.E., Gee J.M.W., Taylor K.M., Barrow D., Wakeling A., Guy S., et al. Acquired resistance to geftinib ('Iressa', ZD1839) in breast cancer cells result from increased IGF1-R signalling and generates cross-resistance to trastuzumab. 2nd international symposium on signal transduction modulators in cancer therapy:2003;Amsterdam, The Netherlands. Vol.; abstract no. O.22
163. Soler-Perez R., Ling Y.H., Lia M., Kroog G., Dai Q., Haigentz M. Molecular mechanisms of resistance to the HER1/EGFR tyrosine kinase inhibitor erlotinib HCI in human cell lines [abstract no. 762]. Proc. ASCO. 22:2003
164. Scappaticci F.A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20:2002;3906-3927
165. Sawyers C.L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17:2003;2998-3010
166. Duyster J., Bai R.Y., Morris S.W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 20:2001;5623-5637
167. Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 18:1999;2343-2350
168. Eng C. RET proto-oncogene in the development of human cancer. J. Clin. Oncol. 17:1999;380-393
169. Parsons R., Simpson L. PTEN and cancer. Methods Mol. Biol. 222:2003;147-166
170. Shimizu A., O'Brien K.P., Sjoblom T., Pietras K., Buchdunger E., Collins V.P., et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59:1999;3719-3723
171. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 300:2003;949
172. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:2003;427-434
173. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243
174. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125
175. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 102:2003;276-283
176. Gorre M.E., Sawyers C.L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr. Opin. Hematol. 9:2002;303-307
177. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843